サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1414010

抗ウイルス剤併用療法の世界市場レポート 2024年

Antiviral Combination Therapy Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.90円
抗ウイルス剤併用療法の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

抗ウイルス剤併用療法市場規模は近年力強く成長しています。2023年の511億5,000万米ドルから2024年には545億米ドルへと、CAGR6.5％で成長する見込みです。過去の期間に見られた成長は、いくつかの要因によるものと考えられます。その要因には、ウイルス感染症の増加、併用治療に対する患者の嗜好の高まり、薬剤耐性の出現、ウイルス学と免疫学の分野における進歩、世界ヘルスケア構想の実施などが挙げられます。これらの要因が相まって、抗ウイルス剤併用療法市場は過去一定期間に拡大しました。

抗ウイルス剤併用療法市場規模は、今後数年間で力強い成長が見込まれます。2028年の年間平均成長率（CAGR）は6.9％で、711億6,000万米ドルに成長します。今後予想される成長には、いくつかの重要な要因があります。これには、ウイルス感染の脅威の継続、研究開発投資の増加、世界の健康への備えへの注力、患者中心のアプローチの採用、新たなウイルス適応症への拡大の可能性などが含まれます。予測期間中に予想される主な動向には、ナノテクノロジーの統合、革新的な組み合わせを探索するための臨床試験の実施、研究開発における共同作業、創薬プロセスにおける人工知能の応用、薬剤耐性の克服を目指した戦略的イニシアチブなどが含まれます。これらの動向は、抗ウイルス剤併用療法市場の成長に影響を与え、成長を牽引するものと思われます。

ウイルス性疾患の急増は、今後数年間における抗ウイルス剤併用療法市場の拡大を促進する見通しです。ウイルスとして知られる微小な感染因子に起因するウイルス性疾患は、効果的な治療アプローチが必要です。抗ウイルス剤の併用療法は、薬剤耐性のリスクを軽減し、治療効率を高める上で重要な役割を果たしています。例えば、2022年6月現在、世界保健機関（WHO）は、B型肝炎またはC型肝炎の感染者は世界で3億5,400万人に上り、C型肝炎の新規感染者は年間150万人に上ると報告しています。このようなウイルス感染の急増は、深刻化する健康課題に対処するための高度な抗ウイルス薬併用療法の必要性を強調しています。

個別化医療に対する需要の高まりは、抗ウイルス剤併用療法市場の成長を促進します。個人の遺伝子やタンパク質の構成に合わせた個別化医療は、病気の予防、発見、治療に革命をもたらします。遺伝子組成の個人差は抗ウイルス療法への反応に影響するため、これらの違いを特定し、治療戦略を最適化する必要があります。例えば、2022年に米国食品医薬品局（FDA）は12の個別化医薬品を認可しました。これは、個別化医療連合（Personalized Medicine Coalition）が強調しているように、新たに承認されたすべての治療用分子実体の約34％を占める。この急増する需要は、治療アプローチを調整することの重要性を強調し、抗ウイルス剤併用療法市場の台頭を促進しています。

2023年の抗ウイルス剤併用療法市場では北米が最大地域でした。アジア太平洋は、予測期間中に抗ウイルス剤併用療法の世界市場レポートにおいて最も急成長する地域となる見込みです。抗ウイルス剤併用療法市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の抗ウイルス剤併用療法市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ブランド
  • ジェネリック
  • 世界の抗ウイルス剤併用療法市場、薬剤併用別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ヌクレオチド逆転写酵素阻害剤/非ヌクレオチド逆転写酵素阻害剤
  • インテグラーゼ阻害剤/ヌクレオチド逆転写酵素阻害剤
  • ヌクレオチド逆転写酵素阻害剤
  • ヌクレオチド逆転写酵素阻害剤/プロテアーゼ阻害剤
  • 他の薬剤の組み合わせ
  • 世界の抗ウイルス剤併用療法市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 携行
  • 静脈内
  • 世界の抗ウイルス剤併用療法市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • 小売薬局
  • その他の流通チャネル
  • 世界の抗ウイルス剤併用療法市場、適応症別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ヒト免疫不全ウイルス
  • 肝炎
  • その他の適応症

第7章 地域および国の分析

  • 世界の抗ウイルス剤併用療法市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の抗ウイルス剤併用療法市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 抗ウイルス剤併用療法市場の競合情勢
  • 抗ウイルス剤併用療法市場の企業プロファイル
    • AbbVie Inc.
    • Bristol-Myers Squibb Company
    • Celltrion Inc.
    • Cipla Inc.
    • F. Hoffmann-La Roche Ltd.

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

目次
Product Code: r11520

“Antiviral Combination Therapy Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antiviral combination therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antiviral combination therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The antiviral combination therapy market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Type: Branded; Generic
  • 2) By Drug Combination: Nucleotide Reverse Transcriptase Inhibitors/Non-Nucleotide Reverse Transcriptase Inhibitors; Integrase Inhibitor/Nucleotide Reverse Transcriptase Inhibitors; Nucleotide Reverse Transcriptase Inhibitors; Nucleotide Reverse Transcriptase Inhibitors/Protease Inhibitor; Other Drug Combinations
  • 3) By Route Of Administration: Oral; Intravenous
  • 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
  • 5) By Indication: Human Immunodeficiency Virus; Hepatitis; Other Indications
  • Companies Mentioned: AbbVie Inc.; Bristol-Myers Squibb Company; Celltrion Inc.; Cipla Inc.; F. Hoffmann-La Roche Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Antiviral combination therapy is a strategic approach involving the use of multiple antiviral medications to effectively address viral infections. This method enhances treatment outcomes by targeting various stages of the virus's life cycle, ultimately minimizing the risk of drug resistance.

The primary categories of antiviral combination therapy are branded and generic. Branded antiviral combination therapies are medications manufactured and marketed under a specific brand name by the manufacturer, holding regulatory approval through a new drug application. These formulations typically consist of a combination of two or more antiviral agents and are employed in treating diverse viral infections, including Human Immunodeficiency Virus (HIV), hepatitis C, and influenza. Examples of branded antiviral combination therapies include Atripla, Harvoni, Complera, Symfi Lo, and Xofluza. These combinations incorporate various drug classes, such as nucleotide reverse transcriptase inhibitors, non-nucleotide reverse transcriptase inhibitors, integrase inhibitors, nucleotide reverse transcriptase inhibitors, and protease inhibitors. They are administered through oral and intravenous routes and are distributed through hospital pharmacies, retail pharmacies, and other channels for the treatment of human immunodeficiency virus, hepatitis, and other viral indications.

The antiviral combination therapy market research report is one of a series of new reports from The Business Research Company that provides antiviral combination therapy market statistics, including the antiviral combination therapy industry's global market size, regional shares, competitors with an antiviral combination therapy market share, detailed antiviral combination therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the antiviral combination therapy industry. This antiviral combination therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antiviral combination therapy market size has grown strongly in recent years. It will grow from $51.15 billion in 2023 to $54.5 billion in 2024 at a compound annual growth rate (CAGR) of 6.5%.The growth observed during the historical period can be attributed to several factors. These include a rise in viral infections, a growing preference among patients for combination treatments, the emergence of drug resistance, advancements in the fields of virology and immunology, and the implementation of global healthcare initiatives. Collectively, these factors contributed to the expansion of the market for antiviral combination therapies during the historical timeframe.

The antiviral combination therapy market size is expected to see strong growth in the next few years. It will grow to $71.16 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. The anticipated growth in the upcoming period can be attributed to several key factors. These include the ongoing threat of viral infections, increased investments in research and development, a focus on global health preparedness, the adoption of patient-centric approaches, and the potential expansion into new viral indications. Major trends expected in the forecast period encompass the integration of nanotechnology, the conduct of clinical trials to explore innovative combinations, collaborative efforts in research and development, the application of artificial intelligence in drug discovery processes, and strategic initiatives aimed at overcoming drug resistance. These trends are poised to influence and drive growth in the market for antiviral combination therapies.

The surge in viral diseases' occurrences is poised to drive the expansion of the antiviral combination therapy market in the forthcoming years. Viral diseases, stemming from microscopic infectious agents known as viruses, necessitate effective treatment approaches. Antiviral combination therapies play a crucial role in mitigating drug resistance risks and bolstering treatment efficiency. For instance, as of June 2022, the World Health Organization (WHO) reported a staggering 354 million individuals globally afflicted by hepatitis B or C infections, with an annual influx of 1.5 million new hepatitis C cases. This surge in viral infections underscores the imperative for advanced antiviral combination therapies to address these escalating health challenges.

The escalating demand for personalized medicine is set to fuel the growth of the antiviral combination therapy market. Personalized medicine, tailored to an individual's genetic or protein makeup, revolutionizes disease prevention, detection, and treatment. Variances in genetic compositions among individuals influence responses to antiviral therapies, prompting the need to identify these distinctions and optimize treatment strategies. For instance, in 2022, the US Food and Drug Administration (FDA) greenlit 12 personalized medicines, constituting roughly 34% of all newly approved therapeutic molecular entities, as highlighted by the Personalized Medicine Coalition. This burgeoning demand underscores the significance of tailoring treatment approaches, fostering the rise of the antiviral combination therapy market.

The market for antiviral combination therapy sees a rising focus on product innovation. Key companies are actively engaged in developing novel technological solutions to fortify their market standing. Gilead Sciences, Inc., a US-based biopharmaceutical firm, received FDA approval in December 2022 for Sunlenca (lenacapavir) in combination with other antiretroviral(s) to treat heavily treatment-experienced (HTE) adults with multi-drug-resistant (MDR) HIV-1 infection.

Prominent entities in the antiviral combination therapy sphere are prioritizing innovative approaches such as AT-527 to maintain their market presence. AT-527, a nucleotide prodrug, effectively hampers RNA virus replication, including SARS-CoV-2 responsible for COVID-19. In October 2021, Atea Pharmaceuticals, a US-based company, unveiled promising outcomes from a Phase 2 clinical trial of AT-527, an oral, direct-acting antiviral aimed at restraining SARS-CoV-2's replication. This drug holds potential as a new treatment avenue for COVID-19 patients and is part of Atea Pharmaceuticals' line of antiviral products for severe viral infections such as COVID-19 and hepatitis C virus (HCV).

In February 2023, Tonix Pharmaceuticals Holding Corporation, a US-based pharmaceutical company specializing in the development of novel therapies and vaccines for central nervous system disorders and infectious diseases, successfully acquired a preclinical infectious disease portfolio from Healion Bio Inc. for $1.2 million. This strategic acquisition is aimed at expanding Tonix Pharmaceuticals' overall portfolio, incorporating a range of next-generation antiviral technology assets. The newly acquired assets include a class of broad-spectrum small molecule oral antiviral drug candidates with a novel host-directed mechanism of action. These candidates can be utilized either as monotherapy or in combination with other antivirals. Healion Bio Inc., the source of the acquired portfolio, is a US-based biotechnology company dedicated to the manufacturing and development of medicines for the treatment and prevention of infectious diseases.

Major companies operating in the antiviral combination therapy market report are AbbVie Inc., Bristol-Myers Squibb Company, Celltrion Inc., Cipla Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline plc, Janssen Global Services LLC, Merck & Co. Inc., Mylan N.V., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Novartis International AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Atea Pharmaceuticals Inc., AstraZeneca plc, Eli Lilly and Company, Moderna Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vir Biotechnology Inc., Johnson & Johnson, Roche Holding AG, Sun Pharmaceutical Industries Ltd., Hetero Drugs Limited, Macleods Pharmaceuticals Ltd., Emcure Pharmaceuticals Ltd., AuroMedics Pharma LLC, Alembic Pharmaceuticals Limited, Zydus lifescience Ltd., Strides Pharma Science Limited, Glenmark Pharmaceuticals Inc., Lupin Pharmaceuticals Inc.

North America was the largest region in the antiviral combination therapy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global antiviral combination therapy market report during the forecast period. The regions covered in the antiviral combination therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the antiviral combination therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The antiviral combination therapy market consists of sales of protease inhibitors, reverse transcriptase inhibitors and integrase inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Antiviral Combination Therapy Market Characteristics

3. Antiviral Combination Therapy Market Trends And Strategies

4. Antiviral Combination Therapy Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Antiviral Combination Therapy Market Size and Growth

  • 5.1. Global Antiviral Combination Therapy Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Antiviral Combination Therapy Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Antiviral Combination Therapy Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Antiviral Combination Therapy Market Segmentation

  • 6.1. Global Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Branded
  • Generic
  • 6.2. Global Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Nucleotide Reverse Transcriptase Inhibitors/Non-Nucleotide Reverse Transcriptase Inhibitors
  • Integrase Inhibitor/Nucleotide Reverse Transcriptase Inhibitors
  • Nucleotide Reverse Transcriptase Inhibitors
  • Nucleotide Reverse Transcriptase Inhibitors/Protease Inhibitor
  • Other Drug Combinations
  • 6.3. Global Antiviral Combination Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Intravenous
  • 6.4. Global Antiviral Combination Therapy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Other Distribution Channels
  • 6.5. Global Antiviral Combination Therapy Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Human Immunodeficiency Virus
  • Hepatitis
  • Other Indications

7. Antiviral Combination Therapy Market Regional And Country Analysis

  • 7.1. Global Antiviral Combination Therapy Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Antiviral Combination Therapy Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Antiviral Combination Therapy Market

  • 8.1. Asia-Pacific Antiviral Combination Therapy Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Antiviral Combination Therapy Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Antiviral Combination Therapy Market

  • 9.1. China Antiviral Combination Therapy Market Overview
  • 9.2. China Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Antiviral Combination Therapy Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Antiviral Combination Therapy Market

  • 10.1. India Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Antiviral Combination Therapy Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Antiviral Combination Therapy Market

  • 11.1. Japan Antiviral Combination Therapy Market Overview
  • 11.2. Japan Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Antiviral Combination Therapy Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Antiviral Combination Therapy Market

  • 12.1. Australia Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Antiviral Combination Therapy Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Antiviral Combination Therapy Market

  • 13.1. Indonesia Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Antiviral Combination Therapy Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Antiviral Combination Therapy Market

  • 14.1. South Korea Antiviral Combination Therapy Market Overview
  • 14.2. South Korea Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Antiviral Combination Therapy Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Antiviral Combination Therapy Market

  • 15.1. Western Europe Antiviral Combination Therapy Market Overview
  • 15.2. Western Europe Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Antiviral Combination Therapy Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Antiviral Combination Therapy Market

  • 16.1. UK Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Antiviral Combination Therapy Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Antiviral Combination Therapy Market

  • 17.1. Germany Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Antiviral Combination Therapy Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Antiviral Combination Therapy Market

  • 18.1. France Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Antiviral Combination Therapy Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Antiviral Combination Therapy Market

  • 19.1. Italy Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Antiviral Combination Therapy Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Antiviral Combination Therapy Market

  • 20.1. Spain Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Antiviral Combination Therapy Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Antiviral Combination Therapy Market

  • 21.1. Eastern Europe Antiviral Combination Therapy Market Overview
  • 21.2. Eastern Europe Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Antiviral Combination Therapy Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Antiviral Combination Therapy Market

  • 22.1. Russia Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Antiviral Combination Therapy Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Antiviral Combination Therapy Market

  • 23.1. North America Antiviral Combination Therapy Market Overview
  • 23.2. North America Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Antiviral Combination Therapy Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Antiviral Combination Therapy Market

  • 24.1. USA Antiviral Combination Therapy Market Overview
  • 24.2. USA Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Antiviral Combination Therapy Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Antiviral Combination Therapy Market

  • 25.1. Canada Antiviral Combination Therapy Market Overview
  • 25.2. Canada Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Antiviral Combination Therapy Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Antiviral Combination Therapy Market

  • 26.1. South America Antiviral Combination Therapy Market Overview
  • 26.2. South America Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Antiviral Combination Therapy Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Antiviral Combination Therapy Market

  • 27.1. Brazil Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Antiviral Combination Therapy Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Antiviral Combination Therapy Market

  • 28.1. Middle East Antiviral Combination Therapy Market Overview
  • 28.2. Middle East Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Antiviral Combination Therapy Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Antiviral Combination Therapy Market

  • 29.1. Africa Antiviral Combination Therapy Market Overview
  • 29.2. Africa Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Antiviral Combination Therapy Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Antiviral Combination Therapy Market Competitive Landscape And Company Profiles

  • 30.1. Antiviral Combination Therapy Market Competitive Landscape
  • 30.2. Antiviral Combination Therapy Market Company Profiles
    • 30.2.1. AbbVie Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Bristol-Myers Squibb Company
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Celltrion Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Cipla Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. F. Hoffmann-La Roche Ltd.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Antiviral Combination Therapy Market Competitive Benchmarking

32. Global Antiviral Combination Therapy Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Antiviral Combination Therapy Market

34. Antiviral Combination Therapy Market Future Outlook and Potential Analysis

  • 34.1 Antiviral Combination Therapy Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Antiviral Combination Therapy Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Antiviral Combination Therapy Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer